CUTANEOUS VASCULAR EFFECTS OF PULSED DYE LASER IN COMBINATION WITH BEVACIZUMAB

脉冲染料激光联合贝伐珠单抗对皮肤血管的影响

• 批准号: 8169483
• 负责人: BERNARD CHOI
• 金额: $ 0.34万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8169483
• 关键词: Aftercare; Angiogenesis Inhibitors; Blood Vessels; Computer Retrieval of Information on Scientific Projects Database; Cutaneous; Dorsal; Dyes; FDA approved; Funding; Grant; Institution; Investigation; Lasers; Lesion; Modeling; Mus; Patients; Physiologic pulse; Recurrence; Research; Research Personnel; Resources; Source; United States National Institutes of Health; bevacizumab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pulsed dye laser treatment of vascular lesions is effective for some patients but multiple treatments are required and most patients do not achieve complete clearance. We have defined several reasons for limited efficacy. One important issue is vessel recurrence after treatment. Bevacizumab is an FDA approved anti-angiogenic agent which might diminish vessel recurrence post-treatment. Current investigations will use a mouse dorsal skinfold model and will be performed with Dr. Bernard Choi.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 脉冲染料激光治疗血管病变对部分患者是有效的，但需要多种治疗，大多数患者没有达到完全清除。我们已经定义了疗效有限的几个原因。一个重要的问题是治疗后血管复发。贝伐单抗是FDA批准的一种抗血管生成药物，可减少治疗后血管复发。目前的研究将使用小鼠背部皮褶模型，并将与Bernard Choi博士一起进行。